4//SEC Filing
Catalyst4, Inc. 4
Accession 0001900201-25-000008
CIK 0001770069other
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 4:16 PM ET
Size
21.7 KB
Accession
0001900201-25-000008
Insider Transaction Report
Form 4
Catalyst4, Inc.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2025-10-28−148,809→ 0 total(indirect: See footnote)→ Voting Common Stock (148,809 underlying) - Conversion
Voting Common Stock
2025-10-28+14,256,288→ 14,256,288 total(indirect: See footnote) - Purchase
Voting Common Stock
2025-10-28$17.00/sh+5,441,176$92,499,992→ 19,697,464 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2025-10-28−1,263,768→ 0 total(indirect: See footnote)→ Voting Common Stock (1,263,768 underlying) - Conversion
Series C Preferred Stock
2025-10-28−5,444,807→ 0 total(indirect: See footnote)→ Voting Common Stock (5,444,807 underlying) - Conversion
Series B-1 Preferred Stock
2025-10-28−275,148→ 0 total(indirect: See footnote)→ Voting Common Stock (275,148 underlying) - Conversion
Series D Preferred Stock
2025-10-28−6,678,910→ 0 total(indirect: See footnote)→ Voting Common Stock (6,678,910 underlying) - Conversion
Series A-1 Preferred Stock
2025-10-28−444,846→ 0 total(indirect: See footnote)→ Voting Common Stock (444,846 underlying)
Footnotes (8)
- [F1]The Series A, A-1, B, B-1, C and D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
- [F2]The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
- [F3]The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
- [F4]The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
- [F5]The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.
- [F6]The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
- [F7]The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
- [F8]The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.
Documents
Issuer
MapLight Therapeutics, Inc.
CIK 0001770069
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001900201
Filing Metadata
- Form type
- 4
- Filed
- Oct 28, 8:00 PM ET
- Accepted
- Oct 29, 4:16 PM ET
- Size
- 21.7 KB